

Genitourinary Drugs Market - 2023-2031

<https://marketpublishers.com/r/GCA26E0A5AA3EN.html>

Date: November 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: GCA26E0A5AA3EN

Abstracts

The Genitourinary Drugs Market was valued at US\$ 31,220.0 million in 2023 and is anticipated to reach US\$ 35,518.8 million by 2031, at a CAGR of 0.016 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Genitourinary Drugs Market.

This report delivers a comprehensive overview of the Genitourinary Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Genitourinary Drugs Market. The Genitourinary Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Genitourinary Drugs Market Scope:

By Disease Type

Erectile Dysfunction

Gonorrhoea

Genital Herpes

Urinary Tract Infections

Urinary Incontinence

Glomerulonephritis

Chronic Renal Failure

Other

By Drug Type

Hormonal Therapy

Impotence Agents

Uterine Relaxants

Urinary Antispasmodics

Urinary pH Modifiers

Uterine Stimulants

Miscellaneous Genitourinary Tract Agents

By Distribution Channel

Hospital Pharmacy

Pharmacy Stores

Others

Key Players

Pfizer Inc.

Eli Lilly and Company

MANUS AKTTEVA BIOPHARMA LLP

Astellas Pharma Inc.

Jubilant Cadista Pharmaceuticals Inc.

Bayer AG

Endo International plc

Teva Pharmaceuticals USA, Inc.

Astellas Pharma US, Inc.

TAIHO PHARMACEUTICAL CO., LTD.

Major Highlights

This report delivers a comprehensive overview of the Genitourinary Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Genitourinary Drugs Market. The Genitourinary Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing

strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Growing Prevalence of Genitourinary Disorders
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Increasing number of counterfeit drugs
 - 4.1.2.2. XX
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion

6. BY DISEASE TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

6.1.2. Market Attractiveness Index, By Disease Type

6.2. Erectile Dysfunction*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Gonorrhoea

6.4. Genital Herpes

6.5. Urinary Tract Infections

6.6. Urinary Incontinence

6.7. Glomerulonephritis

6.8. Chronic Renal Failure

6.9. Other

7. BY DRUG TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

7.1.2. Market Attractiveness Index, By Drug Type

7.2. Hormonal Therapy*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Impotence Agents

7.4. Uterine Relaxants

7.5. Urinary Antispasmodics

7.6. Urinary pH Modifiers

7.7. Uterine Stimulants

7.8. Miscellaneous Genitourinary Tract Agents

8. BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.1.2. Market Attractiveness Index, By Deployment Mode

8.2. Hospital Pharmacy*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Pharmacy Stores

8.4. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution

Channel

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.3.1. U.S.

9.2.3.2. Canada

9.2.3.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.5.1. Germany

9.3.5.2. UK

9.3.5.3. France

9.3.5.4. Italy

9.3.5.5. Spain

9.3.5.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 9.4.5.1. Brazil
- 9.4.5.2. Argentina
- 9.4.5.3. Rest of South America

9.5. Asia-Pacific

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
 - 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.5.5.1. China
 - 9.5.5.2. India
 - 9.5.5.3. Japan
 - 9.5.5.4. South Korea
 - 9.5.5.5. Rest of Asia-Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
 - 9.6.2. Key Region-Specific Dynamics
 - 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

- 11.1. Pfizer Inc.*
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Financial Overview
 - 11.1.4. Key Developments
- 11.2. Eli Lilly and Company
- 11.3. MANUS AKTTEVA BIOPHARMA LLP
- 11.4. Astellas Pharma Inc.
- 11.5. Jubilant Cadista Pharmaceuticals Inc.

11.6. Bayer AG

11.7. Endo International plc

11.8. Teva Pharmaceuticals USA, Inc.

11.9. Astellas Pharma US, Inc.

11.10. TAIHO PHARMACEUTICAL CO., LTD. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Genitourinary Drugs Market - 2023-2031

Product link: <https://marketpublishers.com/r/GCA26E0A5AA3EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCA26E0A5AA3EN.html>